- Belgrade '18
- Vienna '18
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Surgical Outcomes
Session Date/Time: Monday 07/10/2013 | 08:00-09:30
Paper Time: 09:24
Venue: Auditorium (First Floor)
First Author: : M.Piovella ITALY
Co Author(s): : B. Kusa
To study visual outcomes for distance, intermediate and near distance after Synchrony dual-optic accommodative IOL (Abbott Medical Optics, USA) implantation.
C.M.A Centro Microchirurgia Ambulatoriale Via Donizetti 24 , Monza (Italy)
Nineteen patients (32 eyes) underwent topical anaesthesia phacoemulsification and Synchrony dual-optic IOL implantation. Follow up visits were performed at one, three, six, twelve and eighteen months postoperatively. Surgical technique included 5.3 mm capsulorhexis, anterior and posterior capsule cleaning as well as enlargement of the incision with 3.75 mm calibrated metal knife. Contrast sensitivity and occurrence of halos were also assessed. Defocus curve analysis was applied to detect mean accommodative range.
Mean patient age was 71.44 ± 7.27 years. Distance UCVA was 0.53 ± 0.21 at month one, 0.78 ± 0.22 at two months, 0.84 ± 0.18 at three months, 0.87 ± 0.17 at six months, 0.93 ± 0.11 at 1 year and 0.94 ± 0.08 at eighteen months. All patients read 16/20 (EDTRS) without correction at one month, and with + 1.00 D add at six months. No discomfort or complications were noted postoperatively. No contrast sensitivity penalization occurred. Quality of vision study detected moderate halos in 14.3% of the patients.
Synchrony dual-optic accommodative IOL appeared to be clinically safe and effective. UCVA safe for car driving was achieved within one month. Intermediate and near vision were satisfactory within one week. With no contrast sensitivity penalization and diffractions, this IOL may be used in patients with possible high sensitivity to glare and halos.
... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
Please wait while information is loading.